title: Treatment of transplanted spontaneous rat T-cell leukaemia with local administration of recombinant murine interleukin-2.
abstract: Spontaneous rat CD4+CD8-T-cell leukaemia transplanted in syngeneic recipients served as an experimental model system for IL-2 therapy. As a source of IL-2, supernatants from in vitro cultured plasmacytoma cell line X63-m-IL2 secreting constitutively recombinant murine IL-2 were utilized. Administration of IL-2, s.c. to the vicinity of the tumour inoculum, suppressed tumour growth. The tumour-inhibitory IL-2 effects were time- and dose-dependent. When the treatment has started 10 days after the challenge with 10(4) leukaemia cells, IL-2 inhibitory effects on the lymphoma growth in situ were demonstrated by lower tumour weight combined with necrotic changes. No histological signs of lymphoma generalization were found in parenchymatous organs of IL-2-treated rats in contrast to the untreated controls. No histological or functional injuries to the kidneys due to IL-2 administration were found. The results of effector cell phenotyping demonstrated the kinetics of the CD4+/CD8+ ratio characterized by CD4+ T-cell depletion and resulting increase in the percentage of CD8+ PBL.
authors.affiliation: Department of Biology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
authors.forename: B
authors.initials: B
authors.lastname: Otová
authors.forename: A
authors.initials: A
authors.lastname: Panczak
authors.forename: J
authors.initials: J
authors.lastname: Símová
authors.forename: T
authors.initials: T
authors.lastname: Jandlová
authors.forename: J
authors.initials: J
authors.lastname: Bubeník
authors.forename: K
authors.initials: K
authors.lastname: Blazek
authors.forename: J
authors.initials: J
authors.lastname: Schramlová
authors.forename: I
authors.initials: I
authors.lastname: Marinov
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000627:therapeutic use*; D015458:Leukemia, T-Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D009336:Necrosis; D009368:Neoplasm Transplantation; D010954:Plasmacytoma; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D014185:Transplantation, Isogeneic; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins